(E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-butenamide | 56361-02-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-butenamide
• 英文别名: (E)-N-(3,4-dimethoxyphenethyl)but-2-enamide；N-(3,4-dimethoxy-phenethyl)-trans-crotonamide；N-(3,4-Dimethoxy-phenaethyl)-trans-crotonamid；Crotonsaeure-homoveratrylamid；(E)-N-(3,4-dimethoxyphenethyl)-2-butenamide；(E)-N-[2-(3,4-dimethoxyphenyl)ethyl]but-2-enamide
• CAS: 56361-02-5
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: PMRCJJLTSIDYBE-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-butenamide 在 palladium diacetate 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 12.0h， 生成 (E)-N-(2-acetyl-5-{2-[2-(3,4-dimethoxyphenyl)ethylcarbamoyl]-1-methylvinyl}benzofuran-3-yl)-5-methylisoxazole-4-carboxamide
  参考文献：
  名称：

  具有半胱氨酰白三烯2受体拮抗活性的3-乙酰乙酰氨基苯并[b]呋喃衍生物的合成。

  摘要：

  从3-氨基苯并[b]呋喃开始，合成了在3-位具有修饰的三烯系统的新型3-乙酰乙酰氨基苯并[b]呋喃衍生物。由于3-烯丙基乙酰氨基苯并[b]呋喃之间形成氢键，因此作为稳定异构体获得了3-乙酰基乙酰氨基苯并[b]呋喃的烯醇异构体3-[（3-羟基丁-2-烯丙基）氨基]苯并[b]呋喃。羟基和酰胺羰基。通过C-3侧链的C-2取代基的平面性表明烯醇化合物中存在改性的共轭三烯系统。评估了半胱氨酸白三烯1和2受体对这些化合物的拮抗活性。2-（4-氰基苯甲酰基或乙氧基羰基）-3-[（2-氰基-3-羟基丁-2-烯丙基）氨基]苯并[b]呋喃（，）具有中等活性。

  DOI：

  10.1039/b312682j
• 作为产物：
  描述：

  2-丁烯酰氯 、 3,4-二甲氧基苯乙胺 在 三乙胺 作用下， 以 苯 为溶剂， 反应 1.0h， 以96%的产率得到(E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-butenamide
  参考文献：
  名称：

  Synthesis of 2-, 4- and 5-(2-alkylcarbamoyl-1-methylvinyl)-7-alkyloxybenzo[b]furans and their leukotriene B4 receptor antagonistic activity

  摘要：

  合成了变种的苯并[b]呋喃衍生物，这些衍生物在2、4和5位含有(E)-和(Z)-2-烷基氨基甲酰基-1-甲基乙烯基基团，而在7位则含有羧丙氧基或(1-苯基)乙氧基基团，以寻找新型的选择性白三烯B4（LTB4）受体拮抗剂。(E)-2-(2-二乙基氨基甲酰基-1-甲基乙烯基)-7-(1-苯乙氧基)苯并[b]呋喃(4v)对人类BLT2受体(hBLT2)表现出选择性抑制作用。另一方面，(E)-2-乙酰基-4-(2-二乙基氨基甲酰基-1-甲基乙烯基)-7-(1-苯乙氧基)苯并[b]呋喃(7v)则同时抑制人类BLT1受体(hBLT1)和hBLT2。(E)-2-(2-二乙基氨基甲酰基-1-甲基乙烯基)基团大致位于苯并[b]呋喃环的同一平面上，而(E)-4-(2-二乙基氨基甲酰基-1-甲基乙烯基)基团与苯并[b]呋喃环平面之间的扭转角度为45.7°。然而，(Z)-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃表现出不活性。抑制活性取决于2-二乙基氨基甲酰基-1-甲基乙烯基基团的构象。

  DOI：

  10.1039/b503615a

文献信息

• Preparation of 2-, 3-, 4- and 7-(2-alkylcarbamoyl-1-alkylvinyl)benzo[b]furans and their BLT₁and/or BLT₂inhibitory activities
  作者：Kumiko Ando、Yoko Kawamura、Yukiko Akai、Jun-ichi Kunitomo、Takehiko Yokomizo、Masayuki Yamashita、Shunsaku Ohta、Takahiro Ohishi、Yoshitaka Ohishi

  DOI：10.1039/b710935k

  日期：——

  Several 2-alkylcarbamoyl-1-alkylvinylbenzo[b]furans were designed to find a selective leukotriene B4 (LTB4) receptor antagonist. 2-(2-Alkylcarbamoyl-1-alkylvinyl)benzo[b]furans having a substituent group at the 3-position, 4-(2-alkylcarbamoyl-1-methylvinyl)benzo[b]furans having a substituent group at the 3-position, and 7-(2-alkylcarbamoyl-1-methylvinyl)benzo[b]furans and 3-(2-alkylcarbamoyl-1-alkylvinyl)benzo[b]furans were prepared and evaluated for LTB4receptor (BLT1 and BLT2) inhibitory activities. (E)-3-Amino-4-[2-[2-(3,4-dimethoxyphenyl)ethylcarbamoyl]-1-methylvinyl]benzo[b]furan ((E)-17c) showed potent and selective inhibitory activity for BLT2. On the other hand, (E)-7-(2-diethylcarbamoyl-1-methylvinyl)benzo[b]furan ((E)-27a) showed potent inhibitory activity for both BLT1 and BLT2.

  设计了几种2-烷基氨基甲酰基-1-烷基乙烯基苯并[b]呋喃，旨在寻找选择性的白三烯B4（LTB4）受体拮抗剂。合成了在3-位具有取代基的2-(2-烷基氨基甲酰基-1-烷基乙烯基)苯并[b]呋喃、在3-位具有取代基的4-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃、7-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃和3-(2-烷基氨基甲酰基-1-烷基乙烯基)苯并[b]呋喃，并评估了它们对LTB4受体（BLT1和BLT2）的抑制活性。(E)-3-氨基-4-[2-[2-(3,4-二甲氧基苯基)乙基氨基甲酰基]-1-甲基乙烯基]苯并[b]呋喃((E)-17c)显示出对BLT2具有强效且选择性的抑制活性。另一方面，(E)-7-(2-二乙基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃((E)-27a)对BLT1和BLT2均显示出强效的抑制活性。
• Dopaminergic isoquinolines with hexahydrocyclopenta[ ij ]-isoquinolines as D 2 -like selective ligands
  作者：Javier Párraga、Sebastián A. Andujar、Sebastián Rojas、Lucas J. Gutierrez、Noureddine El Aouad、M. Jesús Sanz、Ricardo D. Enriz、Nuria Cabedo、Diego Cortes

  DOI：10.1016/j.ejmech.2016.06.009

  日期：2016.10

  Dopamine receptors (DR) ligands are potential drug candidates for treating neurological disorders including schizophrenia or Parkinson's disease. Three series of isoquinolines: (E)-1-styryl-1,2,3,4-tetrahydroisoquinolines (series 1), 7-phenyl-1,2,3,7,8,8a-hexahydrocyclopenta[ij]-IQs (HCPIQs) (series 2) and (E)-1-(prop-1-en-1-yl)-1,2,3,4- tetrahydroisoquinolines (series 3), were prepared to determine their affinity for both D-1 and D-2-like DR. The effect of different substituents on the nitrogen atom (methyl or allyl), the dioxygenated function (methoxyl or catechol), the substituent at the beta-position of the THIQ skeleton, and the presence or absence of the cyclopentane motif, were studied. We observed that the most active compounds in the three series (2c, 2e, 3a, 3c, 3e, 5c and 5e) possessed a high affinity for D-2-like DR and these remarkable features: a catechol group in the IQ-ring and the N-substitution (methyl or allyl). The series showed the following trend to D-2-RD affinity: HCPIQs > 1-styryl > 1-propenyl. Therefore, the substituent at the beta-position of the THIQ and the cyclopentane ring also modulated this affinity. Among these dopaminergic isoquinolines, HCPIQs stood out for unexpected selectivity to D-2-DR since the Ki D-1/D-2 ratio reached values of 2465, 1010 and 382 for compounds 3a, 3c and 3e, respectively. None of the most active THIQs in D-2 DR displayed relevant cytotoxicity in human neutrophils and HUVEC. Finally, and in agreement with the experimental data, molecular modeling studies on DRs of the most characteristic ligands of the three series revealed stronger molecular interactions with D-2 DR than with D-1 DR, which further supports to the encountered enhanced selectivity to D-2 DR. (C) 2016 Elsevier Masson SAS. All rights reserved.
• MARKARYAN EH. A.; AJRAPETYAN G. K.; ARUSTAMYAN ZH. S.; AVETISYAN A. S., SINTEZY GETEROTSIKL. SOEDIN. (EREVAN), 1981, HO 12, 18-20
  作者：MARKARYAN EH. A.、 AJRAPETYAN G. K.、 ARUSTAMYAN ZH. S.、 AVETISYAN A. S.

  DOI：——

  日期：——
• MARKARYAN EH. A.; AJRAPETYAN G.K., AJKAKAN KIMIAKAN AMSAGIR, ARM. XIM. ZH. <AUKZ-AN>, 1975, 28, HO 4, 317-32+
  作者：MARKARYAN EH. A.、 AJRAPETYAN G.K.

  DOI：——

  日期：——
• MARKARYAN EH. A.; AJRAPETYAN G. K., AJKAKAN KIMIAKAN AMSAGIR, ARM. XIM. ZH., 1978, 31, HO 10, 757-762
  作者：MARKARYAN EH. A.、 AJRAPETYAN G. K.

  DOI：——

  日期：——